티움바이오
Financials
Valuation Metrics
티움바이오's Market Cap is ₩1337B. At end of 2025 it was ₩1799B. Ranked #1090 of 2,421 in KR market (top 45%), #564 of 1,640 on KOSDAQ (top 34%), #124 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 133.67B KRW | KR#1,090/2,421 Sec#124/231 |
| Revenue | 15.00B KRW | KR#2,215/2,421 Sec#164/231 |
| Net Income | -18.40B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 91.02B KRW | KR#1,853/2,421 Sec#148/231 |
| Net Assets | 32.52B KRW | KR#2,148/2,421 Sec#189/231 |
| Employees | 64 | KR#1,936/2,421 Sec#170/231 |
| Value | ||
| P/B | 4.11x | KR#2,199/2,421 Sec#183/231 |
| P/S | 8.91x | KR#2,260/2,421 Sec#162/231 |
| FCF Yield | -11.65% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -56.59% | KR#2,295/2,421 Sec#201/231 |
| ROA | -20.22% | KR#2,244/2,421 Sec#176/231 |
| Op. Margin | -107.28% | KR#2,307/2,421 Sec#176/231 |
| Revenue Growth | 104.49% | KR#80/2,421 Sec#16/231 |
| Financial Health | ||
| Debt Ratio | 179.90% | KR#2,039/2,421 Sec#214/231 |
| Total Debt | 27.26B KRW | KR#1,269/2,421 Sec#98/231 |
| FCF | -15.57B KRW | KR#1,831/2,421 Sec#169/231 |
| Cash | 3.69B KRW | KR#2,111/2,421 Sec#198/231 |
| Current Ratio | 0.93x | KR#1,805/2,421 Sec#176/231 |
| Performance | ||
| 1Y Return | -20.54% | KR#1,278/2,421 Sec#87/231 |
| 1M Return | 2.77% | KR#952/2,421 Sec#69/231 |
| From 52W High | -67.52% | KR#2,132/2,421 Sec#177/231 |
| 1Y MDD | -71.99% | KR#2,068/2,421 Sec#180/231 |
| Trading | ||
| Volume | 55,405 shares | KR#1,081/2,421 Sec#106/231 |
| Trading Value | 249.8M KRW | KR#1,189/2,421 Sec#120/231 |
| Foreign Own. | 3.43% | KR#1,169/2,421 Sec#106/231 |
| Per Share | ||
| EPS | -613 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,083 KRW | KR#2,286/2,421 Sec#207/231 |
Company Info
TiumBio, established in 2016 and headquartered in Seongnam-si, Gyeonggi-do, is a research and development company focused on rare/intractable disease treatments, specially listed on KOSDAQ in 2019. In 2024, it expanded its business by a small merger with natural cosmetics company Petraon, creating the Petraon Care Lab division, while its Protium Science unit offers biopharmaceutical process development services. The company develops immunocancer drugs and endometriosis treatments through its new drug creation system, generating revenue from technology transfer and product sales.